Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III study of HRS-5965 in primary IgA nephropathy
CTR20252059Phase 3Active
- Sponsor
- Chengdu Shengdi
- Start
- Jul 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of HRS-5965 in IgA nephropathy (IgAN), sponsored by Chengdu Shengdi. Started Jul 2025; status: active.
02
Drugs
HRS-5965
03
Conditions
IgA nephropathy (IgAN)
Beyond the preview
Go deeper on CTR20252059.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20252059.